Table 7.
End User Type* | ||||
---|---|---|---|---|
BI | CL | ED | RG | |
Intervention (including environmental regulation) and Remediation | ||||
Descriptions and analyses of the social and physical environment | √ | √ | ||
Triggers and causes of exacerbation | √ | √ | ||
Environmental controls | √ | √ | √ | |
Environmental exposures | √ | √ | √ | √ |
Occupational exposures | √ | √ | √ | |
Baseline burden in typical home; what is typical and what is high in terms of allergens | √ | √ | ||
Connections between clinic data and home data | √ | √ | ||
Issues in building science that affect asthma | √ | √ | ||
Assessment and remediation of the health effects of contaminants | √ | √ | ||
Intervention effectiveness | √ | |||
Social and behavioral influences on case management | √ | |||
Teaching or learning approaches | √ | |||
Environmental justice | √ | √ | ||
Research from all phases in the drug development cycle to support regulation and standard setting | √ | |||
New Drug Development and Regulation | ||||
Clinical applications of drugs | √ | √ | √ | √ |
Effects of medication | √ | √ | √ | √ |
New medications | √ | √ | √ | √ |
Therapeutic product information (e.g., tolerance of therapeutics by patients, adverse effects) | √ | √ | √ | √ |
Changing patterns in asthma prevalence | √ | |||
Pharmacogenetics | √ | √ | √ | √ |
Clinical Practice | ||||
Latest advances in research and implications for practice | √ | √ | √ | √ |
Etiology of severe asthma and implications for asthma management | √ | √ | ||
Viral etiologies of asthma and implications for asthma management | √ | √ | √ | |
Gene-environment interactions | √ | √ | √ | |
Best practices for managing asthma | √ | √ | √ | |
Issues in treatment | √ | √ | √ | |
Issues in adherence | √ | √ | √ | |
Interactions between different care providers | √ | √ |
Business and Industry [BI], Clinical [CL], Education and Advocacy [ED], Regulators [RG]
√ Indicates that at least one end user in this category identified the research content as useful.